Arthritis News - 1999

Based on the findings from ATTRACT (Anti-TNF trial in Rheumatoid Arthritis with Concomitant Therapy), the Food and Drug Administration (FDA) approved the use of Remicade with methotrexate for the treatment of rheumatoid arthritis.

ATTRACT is a double-blind, placebo-controlled, randomized clinical trial involving 428 patients at 34 clinical sites. At week 30, 50% of all patients treated with Remicade and methotrexate, compared to 20% of patients receiving methotrexate alone, achieved an ACR 20 response critieria.

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.